This suggests that the SRC-PRKCD cascade is a novel therapeutic target in Cetuximab-resistant colorectal cancer, and construction of phosphorylation network using phosphoproteomic data will contribute to screening novel kinases as drug targets. Here, PRKCD is linked to colorectal cancer.